Hu, C.; Zhou, A.; Hu, X.; Xiang, Y.; Huang, M.; Huang, J.; Yang, D.; Tang, Y.
LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway. Int. J. Mol. Sci. 2022, 23, 13237.
https://doi.org/10.3390/ijms232113237
AMA Style
Hu C, Zhou A, Hu X, Xiang Y, Huang M, Huang J, Yang D, Tang Y.
LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway. International Journal of Molecular Sciences. 2022; 23(21):13237.
https://doi.org/10.3390/ijms232113237
Chicago/Turabian Style
Hu, Chunsheng, Anting Zhou, Xin Hu, Yu Xiang, Mengjun Huang, Jiuhong Huang, Donglin Yang, and Yan Tang.
2022. "LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway" International Journal of Molecular Sciences 23, no. 21: 13237.
https://doi.org/10.3390/ijms232113237
APA Style
Hu, C., Zhou, A., Hu, X., Xiang, Y., Huang, M., Huang, J., Yang, D., & Tang, Y.
(2022). LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway. International Journal of Molecular Sciences, 23(21), 13237.
https://doi.org/10.3390/ijms232113237